Cellectis S.A. (CLLS) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Unicycive Therapeutics (UNCY) has outperformed Cellectis S.A. (CLLS) over the past year, losing 38.0% versus a loss of 80.4%. Over five years, UNCY leads with a -88.5% price change compared with -89.4% for CLLS. Unicycive Therapeutics is the larger company by market cap ($97.8 million vs $92.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | UNCY |
|---|---|---|
| Share price | $0.9209 | $3.35 |
| Market cap | $92.76M | $97.77M |
| 1-day change | -7.89% | -5.10% |
| YTD return | -80.97% | -41.94% |
| 1-year return | -80.36% | -37.96% |
| 5-year return | -89.40% | -88.53% |
| Forward P/E | — | 4.86 |
| EPS (TTM) | $-1.26 | $-1.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.95M | — |
| Revenue growth (YoY) | +75.76% | — |
| Net income (latest FY) | $-67.59M | $-26.55M |
| Gross margin | 100.00% | — |
| Operating margin | -45.34% | — |
| Net margin | -92.66% | — |
| 52-week high | $5.45 | $8.74 |
| 52-week low | $0.881 | $3.33 |
| Distance from 52-week high | -83.10% | -61.67% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +497.24% | +685.07% |
| Average volume | 115.00K | 963.80K |
| Shares outstanding | 72.73M | 29.18M |
| Employees | 224 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UNCY has outperformed CLLS by 42.4 percentage points over the past year.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
CLLS vs UNCY FAQ
Which is bigger, Cellectis S.A. or Unicycive Therapeutics?
Unicycive Therapeutics (UNCY) is larger, with a market capitalization of $97.77M compared with $92.76M for Cellectis S.A. (CLLS).
Which stock has performed better over the past year, CLLS or UNCY?
UNCY returned -37.96% over the past 12 months, compared with -80.36% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.